Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

BLASTOID-FERTILITY Human Blastoid-Based Platform for Post-Implantation IVF Optimization and Therapeutic Screening

Coordinator
Institut Fuer Molekulare Biotechnologie GmbH, Austria
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101292866

What the project is doing

In the project's own words, from its summary on CORDIS.

Since the first successful IVF birth in 1978, the technology has become a cornerstone of assistedreproduction, driven by the trend toward delayed parenthood. While IVF now accounts for roughly5% of births in Europe, its overall efficiency remains low, with only about 25% of cycles resulting in alive birth. A major bottleneck is the high rate of failure during implantation. Due to the limitedavailability of human embryos and ethical restrictions, IVF optimization has historically relied onmouse models.

However, while pre-implantation development is similar between mice and humans,their post-implantation trajectories diverge significantly, limiting their translational relevance. Thishighlights the urgent need for a reliable, ethical, and predictive model of early human developmentafter implantation. Under the ERC-CoG program, we developed human blastoids, blastocyst-likestructures that accurately mimic key features of pre-implantation human embryogenesis.

The present ERC-PoC project will translatethis platform into a pre-commercial application by screening compounds to improve IVF outcomes. Our expected deliverables include: (i) a validated blastoid-based screening platform, (ii) patented natural compounds with therapeutic potential for IVF, and (iii) abusiness and IP framework for investors, partners, and funding bodies.

Topics

Who is involved

OrganisationCityCountryRole
Institut Fuer Molekulare Biotechnologie GmbHWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI